Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0B8MS
|
|||
| Former ID |
DND000011
|
|||
| Drug Name |
MEDI-547
|
|||
| Synonyms |
MedImmune, MedImmune/AstraZeneca
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1] | |
| Company |
AstraZeneca
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Ephrin type-A receptor 2 (EPHA2) | Target Info | . | [2] |
| KEGG Pathway | Ras signaling pathway | |||
| Rap1 signaling pathway | ||||
| PI3K-Akt signaling pathway | ||||
| Axon guidance | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| Pathway Interaction Database | EphrinA-EPHA pathway | |||
| Arf6 signaling events | ||||
| Direct p53 effectors | ||||
| EPHA forward signaling | ||||
| Stabilization and expansion of the E-cadherin adherens junction | ||||
| EPHA2 forward signaling | ||||
| Reactome | EPH-Ephrin signaling | |||
| EPHA-mediated growth cone collapse | ||||
| EPH-ephrin mediated repulsion of cells | ||||
| WikiPathways | NRF2 pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00796055) Study of MEDI-547 to Evaluate the Safety, Tolerability, and Biologic Activity of IV Administration in Subjects With Relapsed or Refractory Solid Tumors. U.S. NationalInstitutes of Health. | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1822). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.